艾塞那肽与沙格列汀联合二甲双胍治疗2型糖尿病患者的疗效与安全性比较

被引：28

作者：

张先祥 ^{[1
]}

阳皓 ^{[1
]}

杨刚毅 ^{[2
]}

叶菲 ^{[2
]}

李伶 ^{[3
]}

李钶 ^{[2
]}

李彦 ^{[1
]}

罗涌 ^{[1
]}

机构：

[1] 重庆三峡中心医院内分泌科

[2] 重庆医科大学附属第二医院内分泌科

[3] 重庆医科大学检验系临床生化教研室

来源：

第三军医大学学报 | 2013年 / 35卷 / 14期

关键词：

艾塞那肽; 沙格列汀; 二甲双胍; 2型糖尿病;

D O I：

10.16016/j.1000-5404.2013.14.012

中图分类号：

R587.1 [糖尿病];

学科分类号：

100201 [内科学];

摘要：

目的评估艾塞那肽与沙格列汀联合二甲双胍治疗2型糖尿病(type 2 diabetes mellitus,T2DM)患者的有效性与安全性。方法收集2011年1月到2012年12月于我院内分泌科门诊就诊的T2DM患者,按随机数字表法分为两组:艾塞那肽组37例(男性17例,女性20例),年龄(55.6±8.2)岁;沙格列汀组37例(男性15例,女性22例),年龄(57.6±8.6)岁。两组均联合二甲双胍治疗16周。主要疗效指标为治疗前后糖化血红蛋白(glycosylated hemoglobin,HbA1c)的变化,次要疗效指标包括受试者达到HbA1c<7.0%的人数百分比及空腹血糖(fasting plasma glucose,FPG)的降幅。结果治疗后艾塞那肽组T2DM患者HbA1c下降(0.75±0.69)%,沙格列汀组患者HbA1c下降(0.59±0.89)%;艾塞那肽组FPG下降幅度高于沙格列汀组[(1.79±1.29)mmol/L vs(1.54±1.75)mmol/L,P<0.05]。两组HbA1c的达标率(38.2%vs 37.0%)无显著性差异(P>0.05);艾塞那肽对控制体质量及收缩压的效果优于沙格列汀(P<0.05)。两组均无严重低血糖事件发生,报告不良事件的发生无统计学差异(P>0.05)。结论艾塞那肽与沙格列汀均能有效控制T2DM患者血糖水平,安全性好;艾塞那肽较沙格列汀有利于降低体质量和血压。

引用

页码：1531 / 1534

页数：4

共 10 条

[1]

DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis [J].

Monami, Matteo ;

Lamanna, Caterina ;

Desideri, Carla Maria ;

Mannucci, Edoardo .

ADVANCES IN THERAPY, 2012, 29 (01) :14-25

[2]

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress [J].

Bunck, Mathijs C. ;

Corner, Anja ;

Eliasson, Bjorn ;

Heine, Robert J. ;

Shaginian, Rimma M. ;

Wu, Yan ;

Yan, Ping ;

Smith, Ulf ;

Yki-Jarvinen, Hannele ;

Diamant, Michaela ;

Taskinen, Marja-Riitta .

ATHEROSCLEROSIS, 2010, 212 (01) :223-229

[3]

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-; PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor.[J]..Molecular and Cellular Endocrinology.2010, 1

[4]

Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway [J].

Gupta, Nitika Arora ;

Mells, Jamie ;

Dunham, Richard M. ;

Grakoui, Arash ;

Handy, Jeffrey ;

Saxena, Neeraj Kumar ;

Anania, Frank A. .

HEPATOLOGY, 2010, 51 (05) :1584-1592

[5]

Unraveling the Science of Incretin Biology.[J].Michael A. Nauck.European Journal of Internal Medicine.2009,

[6]

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].

Buse, John B. ;

Rosenstock, Julio ;

Sesti, Giorgio ;

Schmidt, Wolfgang E. ;

Montanya, Eduard ;

Brett, Jason H. ;

Zychma, Marcin ;

Blonde, Lawrence .

LANCET, 2009, 374 (9683) :39-47

[7]

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? [J].

Giugliano, Dario ;

Standl, Eberhard ;

Vilsboll, Tina ;

Betteridge, John ;

Bonadonna, Riccardo ;

Campbell, Ian W. ;

Schernthaner, Gerit-Holger ;

Staels, Bart ;

Trichopoulou, Antonia ;

Farinaro, Eduardo .

ACTA DIABETOLOGICA, 2009, 46 (03) :173-181

[8]

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes [J].

Nathan, David M. ;

Buse, John B. ;

Davidson, Mayer B. ;

Ferrannini, Ele ;

Holman, Rury R. ;

Sherwin, Robert ;

Zinman, Bernard .

DIABETES CARE, 2009, 32 (01) :193-203

[9]

Toll-Like Receptor 2 Mediates Apolipoprotein CIII–Induced Monocyte Activation: Retracted.[J].Akio Kawakami;Mizuko Osaka;Masanori Aikawa;Satoshi Uematsu;Shizuo Akira;Peter Libby;Kentaro Shimokado;Frank M. Sacks;Masayuki Yoshida.Circulation Research.2008, 12

[10]

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes [J].

Fehse, F ;

Trautmann, M ;

Holst, JJ ;

Halseth, AE ;

Nanayakkara, N ;

Nielsen, LL ;

Fineman, MS ;

Kim, DD ;

Nauck, MA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (11) :5991-5997

← 1 →